Breast Cancer Res Treat
Breast Cancer Research and Treatment
0167-6806
1573-7217
Springer US
Boston


2001218
17912636
9700
10.1007/s10549-007-9700-y
Review


Letrozole as upfront endocrine therapy for postmenopausal women with hormone-sensitive breast cancer: BIG 1-98

Koeberle
Dieter

+41-71-4941111
+41-71-4946325
dieter.koeberle@kssg.ch



Thuerlimann
Beat

beat.thuerlimann@kssg.ch



Department of Internal Medicine, Division Oncology/Hematology, Kantonsspital, CH-9007 St. Gallen, Switzerland 

3
10
2007

10
2007

105
Suppl 1
55
66
3
1
2007

17
7
2007


© Springer Science+Business Media, LLC 2007

P
P
P
®
) is currently recommended as a part of standard adjuvant therapy for postmenopausal women with endocrine-responsive breast cancer and has recently been approved in the early adjuvant setting in both Europe and the United States. A subsequent analysis after additional follow-up will address the question of monotherapy versus sequential therapy.

Keywords
Adjuvant therapy
Aromatase inhibitor
Breast cancer
BIG 1-98
Letrozole
Tamoxifen

issue-copyright-statement
© Springer Science+Business Media, LLC. 2007




Introduction and rationale
1
2
].
1
1
3
5
6
7
8
9
10
].
11
15
12
11
16
17
]. This superiority of letrozole over tamoxifen in the advanced setting led to the hypothesis that this AI may also be superior to tamoxifen when administered in the adjuvant setting.
The Breast International Group (BIG) 1-98 was designed, coordinated, analyzed, and reported by an independent academic group and currently is the largest ongoing adjuvant trial in breast cancer investigating the role of an AI. This review summarizes the design and results from the primary core analysis of the BIG 1-98 trial, which compared monotherapy with letrozole to monotherapy with tamoxifen and identified letrozole as a better alternative to tamoxifen in this setting. It also summarizes some of the additional published research using the BIG 1-98 database.

Trial design and patients
1
Fig. 1
BIG-98 trial design




2
Fig. 2
18
, Supplementary Appendix]





End points
The primary end point of the trial was disease-free survival (DFS), defined as the time from randomization to first occurrence of: invasive recurrence in ipsilateral breast, chest wall, regional site (internal mammary/axilla), or distant site (including ipsilateral supraclavicular); contralateral breast cancer (invasive); second malignancy (non-breast); or death without prior cancer event. Protocol-specified secondary end points in the BIG 1-98 trial were: overall survival (OS), defined as time from randomization to death from any cause; systemic DFS, defined as time from randomization to distant recurrence; second non-breast malignancy or death from any cause (ignoring local and contralateral-breast events); and safety. Three additional end points were defined in the statistical analysis plan: (1) DFS excluding second, non-breast malignancies; (2) time to recurrence, defined as time from randomization to first breast cancer recurrence (excluding second, non-breast cancers and censoring data on patients who died without a prior cancer event); and (3) time to distant recurrence, defined as the time from randomization to the first breast cancer recurrence at a distant site.

Efficacy analyses
Primary, secondary, and additional end points
P
3
P
P
4
Fig. 3
18
] with permission from the Massachusetts Medical Society



Fig. 4
18
] with permission from the Massachusetts Medical Society





Subgroup analyses
4
18
19
20
18
21
21
].
22
P
P
P
P
P
22
].

Letrozole-only versus tamoxifen-only arms
P
P
P
P
1
23
Table 1
n
n
23
]

End point
Events 
Hazard ratio
95% CI
P
-value

Let
Tam


DFS (primary protocol definition)
352
418
0.82
0.71–0.95
0.007

Overall survival
194
211
0.91
0.75–1.11
0.35

Systemic DFS
331
374
0.87
0.75–1.01
0.07

DFS (ignoring second non-breast cancer)
307
364
0.83
0.71–0.96
0.01

Time to recurrence
231
291
0.78
0.65–0.92
0.004

Time to distant recurrence
193
234
0.81
0.67–0.98
0.03



DFS
 Let
 Tam
 CI
 confidence interval





Safety
2
18
24
Table 2
18
]

Adverse event 
Incidence of any grade (%)
P
-value

n
 = 3,975)
n
 = 3,988)


Cerebrovascular accident or transient ischemic attack
1.0
1.0
0.91

Thromboembolic event
1.5
3.5
<0.001

Cardiac event
4.1
3.8
0.61

Other cardiovascular event
0.5
0.2
0.04

Vaginal bleeding
3.3
6.6
<0.001

Hot flashes
33.5
38.0
<0.001

Night sweats
13.9
16.2
0.004

Fracture
5.7
4.0
<0.001

Arthralgia
20.3
12.3
<0.001





P
P
P
P
 = 0.004).
P
 < 0.001) and a shorter time to first fracture.
18
18
25
]. Thus, median changes in cholesterol values from baseline were 0, 0, and −1.8% at 6, 12, and 24 months in the letrozole group and −12.0, −13.5, and −14.1% in the tamoxifen group.
P
P
18
].

Discussion 
Clinical implications of BIG 1-98
18
23
], demonstrate a significant benefit of letrozole over tamoxifen. Letrozole is at least as well-tolerated as tamoxifen, offering patients and physicians a true alternative. However, bone metabolism is differently affected by letrozole and tamoxifen. Patients receiving AIs are at increased risk for bone loss and osteoporosis and should therefore receive appropriate monitoring and medical intervention as part of daily practice.
26
27
26
27
27
], nor do the guidelines provide recommendations as concerns the optimal use of the AIs as upfront monotherapy or sequenced with tamoxifen.
28
29
]. At a median follow-up of 68 months, no survival advantage has been observed in the ATAC trial, and it remains an open question whether the DFS advantage observed in AI trials will translate into an OS advantage.
18
28
30
31
]. The adjuvant FACE trial compares upfront therapy with letrozole 2.5 mg with anastrozole 1 mg daily for up to 5 years in postmenopausal, HR+, node-positive breast cancer patients. In addition, recruitment of a direct comparison of anastrozole and exemestane (MA.27) has been completed recently.
32
12
17
33
34
35
36
33
37
38
]). In these sequential trials, events are included in the analysis from treatment start and not from point of switch after 2–3 years of tamoxifen. Sequential and switch trials investigate obviously the same intervention but are conducted in different patient groups, thus, results are expected to be different and are different indeed.
39
] and from an updated analysis of ABCSG-8, become available.


Conclusions
18
]. The comparison between the monotherapy and the sequential treatment arms within the BIG 1-98 trial are eagerly awaited and are expected to have an important impact on the management of breast cancer.


Acknowledgement
We greatly appreciate the help of Miss Sharon Thomas (sthomas@ghgroup.com) in preparing the manuscript.

BIG 1-98 Collaborative Group Participants
Steering Committee:
 B. Thürlimann (Chair), L. Blacher, M. Castiglione, A. S. Coates, T. Cufer, J. F. Forbes, R. D. Gelber, A. Goldhirsch, A. Hiltbrunner, S. B. Holmberg, A. Keshaviah, R. Maibach, A. Martoni, L. Mauriac, H. T. Mouridsen, K. N. Price, M. Rabaglio, A. Santoro, I. E. Smith, C. Straehle, G. Viale.
Novartis: H. A. Chaudri-Ross, A. Covelli, D. B. Evans, W. Hackl, E. Raman, M.G. Porro.
IBCSG Scientific Committee:
 A. Goldhirsch, A. S. Coates (Co-Chairs), L. Blacher, M. Castiglione, J. F. Forbes, R. D. Gelber, B. A. Gusterson, A. Hiltbrunner, C. Hürny, E. Murray, K. N. Price, M. Rabaglio, R. Studer, G. Viale, A. Wallgren.
IBCSG Foundation Council:
 B. Thürlimann (President), M. Castiglione, A. S. Coates, J. P. Collins, H. Cortés Funes, R. D. Gelber, A. Goldhirsch, M. Green, A. Hiltbrunner, S. B. Holmberg, D. K. Hossfeld, I. Láng, J. Lindtner, F. Paganetti, C.-M. Rudenstam, R. Stahel, H.-J. Senn, A. Veronesi.
Coordinating Center
 (Berne, Switzerland): M. Castiglione (CEO), A. Hiltbrunner (Director), M. Rabaglio, G. Egli, B. Cliffe, S. Ribeli-Hofmann, F. Munarini, R. Kammler, R. Studer, B. Ruepp, R. Maibach, N. Munarini.
Statistical Center
 (Dana-Farber Cancer Institute, Boston, MA, USA): R. D. Gelber (Group Statistician), K. N. Price (Director of Scientific Administration), A. Keshaviah (Trial Statistician), H. Litman, H. Huang, L. J. Somos, B. Timmers, L. Nickerson.
Data Management Center
 (Frontier Science & Technology Research Foundation, Amherst, NY, USA): L. Blacher (Director of Data Management), T. Heckman Scolese (Coordinating Data Manager), M. Belisle, M. Caporale, J. Celano, L. Dalfonso, L. Dooley, S. Fischer, K. Galloway, J. Gould, R. Hinkle, M. Holody, G. Jones, R. Krall, S. Lippert, J. Meshulam, L. Mundy, A. Pavlov-Shapiro, K. Scott, M. Scott, S. Shepard, J. Swick, L. Uhteg, D. Weinbaum, C. Westby, T. Zielinski.
Central Pathology Review Office
 (University of Glasgow, Glasgow, UK): B. A. Gusterson, E. Mallon; (European Institute of Oncology, Division of Pathology, Milano, Italy): G. Viale, P. Dell’Orto, M. Mastropasqua, B. Del Curto.
Data and Safety Monitoring Committee: 
D.F. Hayes, J.E. Garber, S.W. Lagakos, I. Lindgren.
Study Support
 (Novartis Corp. Basel, Switzerland): E. Waldie, I. van Hoomissen, M. De Smet, W. Schmidt, A. Bolton, W. Hackl.

Breast International Group (BIG)
International Breast Cancer Study Group (IBCSG)
Australian New Zealand Breast Cancer Trials Group (ANZ BCTG): 
Board Chair: R. D. Snyder, Group Co-ordinator: J. F. Forbes, Chair Scientific Advisory Committee: A. S. Coates; ANZ BCTG Operations Office (Newcastle, Australia): D. Lindsay (Head Data Management), D. Preece (Senior Study Coordinator), J. Cowell, D. Talbot, A. Whipp.
Australia: The Cancer Council Victoria
Launceston General Hospital
Liverpool Hospital
 Mount Hospital
Nepean Cancer Care Centre
Newcastle Mater Hospital
Prince of Wales Hospital
Princess Alexandra Hospital
 Royal Adelaide Hospital
Royal Brisbane and Women’s Hospital
Royal Hobart Hospital
Royal Perth Hospital
Sir Charles Gairdner Hospital
Toowoomba Hospital
Westmead Hospital, Sydney
, NSW: P. Harnett, V. Ahern, H. Gurney, N. Wilcken.
New Zealand:
Auckland Hospital
Christchurch Hospital
Waikato Hospital
, Hamilton: I. D. Campbell, L. Gilbert, R. Gannaway, M. Jameson, I. Kennedy, J. Long, G. Round, L. Spellman, D. Whittle, D. Woolerton.
Brazil: Hospital de Clinicas de Porto Alegre
, Porto Alegre: C. Menke, J. Biazús, R. Cericatto, J. Cavalheiro, N. Xavier, A. Bittelbrunn, E. Rabin.
Chile: Chilean Cooperative Group for Oncologic Research, GOCCHI: 
Clinica Las Condes
 Hospital DIPRECA
Hospital San Juan de Dios
 IRAM/Instituto de Radiomedicina, 
 Vitacura, Santiago: R. Baeza, R. Arriagada, P. Olfos, J. Solé, E. Vinés, C. Mariani.
Hungary: National Institute of Oncology
, Budapest: I. Láng, E. Hitre, E. Szabó, Z. Horváth, E. Ganofszky, E. Juhos.
Italy: Centro di Riferimento Oncologico
Ospedali Riuniti di Bergamo
Ospedale degli Infermi
 Spedali Civili
U. O. Medicina Oncologica, Ospedale Capri, Ospedale Mirandola
 Ospedale di Cattolica “Cervesi”, Cattolica
Ospedale Civile
Ospedale “A. Manzoni” Lecco
 Istituto Europeo di Oncologia
Ospedale Infermi
, Rimini: A. Ravaioli, L. Gianni.
Peru: Instituto de Enfermedades Neoplásicas
, Lima: H. Gome.
Slovenia: Institute of Oncology
, Ljubljana: T. Cufer, B. Pajk, J. Cervek.
South Africa: Groote Schuur Hospital and University of Cape Town
Sandton Oncology Centre
Cancer Association of South Africa
.
Sweden: West Swedish Breast Cancer Study Group
 Sahlgrenska U Hospital
 Boras Hospital
 Karlstads Hospital
 Kungalvs Hospital
, Kungalvs: B. Lindberg.
Switzerland: Swiss Group for Clinical Cancer Research (SAKK)
Kantonsspital Aarau, Zentrum f. Onkologie
University Hospital Basel
Institute of Oncology of Southern Switzerland: Ospedale San Giovanni
Ospedale Regionale di Lugano (Civico & Italiano)
Ospedale Regionale Beata Vergine
Ospedale Regionale La Carità
Istituto Cantonale di Patologia
Inselspital
Kantonsspital Olten
Bürgerspital
 Spital Thun-Simmental AG Thun
Hôpital Cantonal Universitaire HCUG
Rätisches Kantons- und Regionalspital
Centre Pluridisciplinaire d’Oncologie
Kantonsspital St. Gallen
Kantonales Spital Herisau
Stadtspital Triemli, Zürich
Universitätsspital Zürich
, Zürich: B. C. Pestalozzi, M. Fehr, R. Caduff, Z. Varga, R. Trüb, D. Fink.
Swiss Private MDs
: Private Praxis, Zürich: B. A. Bättig; Sonnenhof-Klinik Engeried, Berne: K. Buser; Frauenklinik Limmattalspital, Schlieren: N. Bürki; Private Praxis, Birsfelden: A. Dieterle; Private Praxis, Biel: L. Hasler; Private Praxis, Baar: M. Mannhart-Harms; Brust-Zentrum, Zürich: C. Rageth; Private Praxis, Berne: J. Richner; Private Praxis, Bellinzona: V. Spataro; Private Praxis, Winterthur: M. Umbricht.
United Kingdom: King’s College Hospital/Breast Unit, London
: P. Ellis, S. Harris, N. Akbar, H. McVicars, C. Lees, R. Raman, G. Crane.


Danish Group (DBCG)
Rigshospitalet
Vejle Hospital
Odense University Hospital
KAS Herlev/Herlev University Hospital
Aalborg Sygehus Syd
Hilleroed Hospital
Aarhus University Hospital
Roskilde County Hospital
Central Hospital
Naestved Central Hospital
Soenderborg Sygehus
Central Hospital
Viborg Sygehus
Landspitali University Hospital
, Reykjavik, Iceland: J. Johansson.

French Group (FNCLCC)
Institut Bergonié
 Centre Hospitalier de la Côte Basque
 Centre Jean Perrin
 Centre Georges François Leclerc
 Centre Oscar Lambret
 CHRU
 Centre Léon Bérard
 Centre Hospitalier Meaux
 C.H.G. André Boulloche
 Centre Paul Lamarque
 Clinique Francheville
 Hôpital de la Milétrie
 Centre Eugène Marquis
 Centre Henri Becquerel
 Centre René Gauducheau
 Centre Claudius Régaud
, Toulouse: L. Gladieff, N. Lignon.

North Yorkshire Group
 Harrogate District Hospital
 Huddersfield Royal Infirmary
 Castlehill Hospital
 Airedale General Hospital
 Leeds General Infirmary
 St. James’s University Hospital
 Weston Park Hospital
, Sheffield: R. E. Coleman.

Independent Centers/Groups
Argentina: Centro Oncológico Confidence
 Hospital Allemán
 Hospital Británico
 Hospital Evita
 Hospital Posadas
 Hospital Zubizarreta
 Instituto Dr. Estevez
 Instituto Oncológico Dr. Angel H. Roffo
 Sanatorio Municipal Julio A. Mendez
 Centro Privado de Ginecología
 Hospital Privado de Córdoba
 Instituto Modelo de Ginecología y Obstetricia
 Fundación Mainetti-Centro Oncológico de Excelencia
 Hospital Privado de la Comunidad
 Escuela de Medicina Nuclear (COIR)
 Centro Oncológico de Rosario
 Hospital Provincial de Rosario
 Clínica Especializada ISIS
 Hospital Regional de Concepción
 Instituto de Maternidad y Ginecología Nuestra Señoras de las Mercedes
, Tucumán: L. Silberman.
Australia: Flinders Medical Centre
 Queen Elizabeth Hospital
 The Canberra Hospital
 The Geelong Hospital
 Royal Melbourne Hospital
 Western General Hospital
 Newcastle Mater Hospital
 Royal Perth Hospital
 St. George Hospital
 St. Vincent’s Hospital
 Murray Valley Private Hospital
 Princess Alexandra Hospital
, Woolloongabba, QLD: E. Walpole, D. Thompson.
Belgium: Institut Jules Bordet
University Hospitals Leuven
Les Cliniques Saint-Joseph ASBL
Clinique du Parc Léopold
C. H. Etterbeek-Ixelles
Service d’Oncologie Clinique Notre-Dame
C. H. U. André Vèsale
, Montigny-Le Tilleul: D. Brohèe.
Canada: Cambridge Memorial Hospital
 CHUM- Campus Notre-Dame
 Hôpital Maisonneuve-Rosemont
, Montreal: P. Dubé.
Chile: Fundacion Lopez Perez
 Hospital Carlos Van Buren
, Valparaiso: M. León Prieto.
Czech Republic: Institute of Oncology
 Dept. of Clinical and Radiation Oncology
 Centre of Breast Diseases
 Institute of Radiation Oncology
 University Hospital
 University Hospital Prague
: L. Petruzelka, E. Sedlackova, H. Honova.
Germany: 
Onkologische Gemeinschaftspraxis
Zentralklinikum/Frauenklinik
Universitätsklinikum Essen
Universitäts-Frauenklinik d. JLU Giessen
Onkologische Gemeinschaftspraxis
Martin-Luther-Universität Halle-Wittenberg
Universitätskliniken des Saarlandes
Universitäts-Frauenklinik und Poliklinik Universitätskrankenhaus Eppendorf
Kliniken d. Med. Hochschule, Frauenklinik
Krankenanstalt Mutterhaus der Borromäerinnen
Gynäkologische Abteilung des St. Josefshospital
Gynäkologische Abteilung d. Marienhospitals, Universität Witten-Herdecke
, Witten: J. Hackmann, W. Bader.
Hungary: SZOTE Onkoterápiás Klinika
 BM Központi Kórház
 SOTE Radiológiai és Onkoterápiás Klinika
 Uzsoki Utcai Kórház
 Almási Balogh Pál Kórház
 Területi Kórház Onkologia
 Szent Borbála Kórház, Megyei Onkológiai Gondozó
, Tatabánya: Á. Dani.
Italy: Policlinico S. Orsola-Malpighi
 Ospedale S. Croce
 Istituto Clinica Humanitas
 Azienda Ospedaliera San Filippo Neri
 Az. Ospedaliera Treviglio-Caravaggio
 Policlinico Universitario (PUDG)
 Ospedale di Torrette
 Universitiy of Cagliari, Policlinico Universitario
 Ospedale Civile Feltre
 Istituto Nazionali Ricerca Cancro
 Istituto Nazionale dei Tumori
 Azienda Ospedaliera di Parma
 Azienda Ospedaliera “S. Salvatore”
 Azienda Ospedaliera “Ospedale di Circolo e Fondazione Macchi” Varese
 Universitiy of Cagliari, Policlinico Universitario
 Ospedale Maggiore
 Policlinico Universitario
 Ospedale Civile dello Spirito Santo
 Azienda Ospedaliera Santa Maria Nuova, Reggio Emilia
 Azienda Ospedaliera Desenzano del Garda
 Ospedale Civile ASL 20
, Tortona: M. G. Pacquola.
Netherlands: Ziekenhuis Leyenburg
 Catharina Ziekenhuis
 St. Anna Ziekenhuis
 Tweesteden Ziekenhuis
 Maxima Medisch Centrum
, Veldhoven: R. H. M. Roumen.
New Zealand: Dunedin Hospital
Waikato Hospital
, Hamilton: I. Kennedy, I. D. Campbell, L. Gilbert, R. Gannaway, M. Jameson, J. Long, G. Round, L. Spellman, D. Whittle, D. Woolerton.
Poland: Department of Oncology and Radiotherapy, Medical University of Gdansk
 Rydygier’s Memorial Hospital
 Klinika Nowotworów Piersi i, Chirurgii Rekonstrukcyjnej-Warszawa
 Centrum Onkologii w Bydgoszczy, Oddzial Onkologii Klinicznej
 Collegium Medicum Jagiellonian University
 Oddzial Kliniczny Onkologiczny, Centralnego Szpitala Klinicznego Wojskowej, Akademii Medycznej-Warszawa
 Dolnoslaskie Centrum Onkologii
, Wroclaw: E. Filypczyk-Cisarz, K. Pajak.
Portugal: Hospital de S. João, Porto
Instituto Português de Oncologia de Coimbra
Instituto Português de Oncologia de Lisboa
Hospital Geral de Santo António
, Porto: F. Marques.
Russia: Cancer Research Centre
Moscow Municipal Hospital No. 62
Moscow Research Institute of Diagnostics and Surgery
N. M. Emmanuel Institute of Biochemical Physics
N.N. Petrov Research Institute of Oncology
Saint-Petersburg City Oncological Dispensary
, St. Petersburg: G. Manikhas, G. Dolmatov.
South Africa: Mamma Clinic, Tygerberg Hospital
 Southern Cross Hospital
 Pretoria Academic Hospital
 Pretoria East Hospital
 Eastern Cape Oncology Centre
, Port Elizabeth: K. Maart.
Spain:
Hospital Ruber Internacional
Hospital Son Dureta
Centro Oncológico Integral de Madrid (CONIM)
Hospital Universitario San Carlos
Hospital Central de Asturias
, Oviedo: J. Fra, J. M. Vieitez, E. Esteban, A. J. Lacave.
Switzerland: Universitätsfrauenklinik
 Klinik am Park
, Zürich: U. Breitenstein.
Turkey: Ankara University Ibni Sina Hospital
 Hacettepe University Oncology Institute
 Istanbul University Oncology Institute
 Ege University Medical School
 9 Eylul University Medical School
, Izmir: O. Harmancioglu, A. U. Yilmaz.
United Kingdom: The Royal Marsden Hospital
 Royal Marsden NHS Trust
 University of Dundee
 Christie Hospital NHS Trust, South Manchester University Hospital Trust
 Royal Bournemouth Hospital
 North Middlesex Hospital
, London: F. Neave.
Uruguay: Hospital de Clinicas Dr. Manuel Quintela
, Montevideo, Uruguay: G. Sabini.


References
1.
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
Lancet
2005
365
1687
1717
10.1016/S0140-6736(05)66544-0

15894097


2.
Demonty
G

Bernard-Marty
C

Puglisi
F

Mancini
I

Piccart
M


Progress and new standards of care in the management of HER-2 positive breast cancer
Eur J Cancer
2007
43
497
509
10.1016/j.ejca.2006.10.020

17223541


3.
Boccardo
F

Bruzzi
P

Rubagotti
A

Nicolo
GU

Rosso
R


Estrogen-like action of tamoxifen on vaginal epithelium in breast cancer patients
Oncology
1981
38
281
285

7266969


4.
Helgason
S

Wilking
N

Carlstrom
K

Damber
MG

Schoultz
B


A comparative study of the estrogenic effects of tamoxifen and 17 beta-estradiol in postmenopausal women
J Clin Endocrinol Metab
1982
54
404
408

6798066


5.
Ellmen
J

Hakulinen
P

Partanen
A

Hayes
DF


Estrogenic effects of toremifene and tamoxifen in postmenopausal breast cancer patients
Breast Cancer Res Treat
2003
82
103
111
10.1023/B:BREA.0000003957.54851.11

14692654


6.
Fisher
B

Costantino
JP

Redmond
CK

Fisher
ER

Wickerham
DL

Cronin
WM


Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14
J Natl Cancer Inst
1994
86
527
537
10.1093/jnci/86.7.527

8133536


7.
Pritchard
KI

Paterson
AH

Paul
NA

Zee
B

Fine
S

Pater
J


Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group
J Clin Oncol
1996
14
2731
2737

8874334


8.
Bushnell
CD

Goldstein
LB


Risk of ischemic stroke with tamoxifen treatment for breast cancer: a meta-analysis
Neurology
2004
63
1230
1233

15477543


9.
Fisher
B

Dignam
J

Bryant
J

Wolmark
N


Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial
J Natl Cancer Inst
2001
93
684
690
10.1093/jnci/93.9.684

11333290


10.
Anderson
WF

Jatoi
I

Devesa
SS


Distinct breast cancer incidence and prognostic patterns in the NCI’s SEER program: suggesting a possible link between etiology and outcome
Breast Cancer Res Treat
2005
90
127
137
10.1007/s10549-004-3777-3

15803359


11.
Mouridsen
H

Sun
Y

Gershanovich
M

Perez-Carrion
R

Becquart
D

Chaudri-Ross
HA

Lang
R


Superiority of letrozole to tamoxifen in the first-line treatment of advanced breast cancer: evidence from metastatic subgroups and a test of functional ability
Oncologist
2004
9
489
496
10.1634/theoncologist.9-5-489

15477633


12.
Mouridsen
H

Gershanovich
M

Sun
Y

Perez-Carrion
R

Boni
C

Monnier
A

Apffelstaedt
J

Smith
R

Sleeboom
HP

Jaenicke
F

Pluzanska
A

Dank
M

Becquart
D

Bapsy
PP

Salminen
E

Snyder
R

Chaudri-Ross
H

Lang
R

Wyld
P

Bhatnagar
A


Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group
J Clin Oncol
2003
21
2101
2109
10.1200/JCO.2003.04.194

12775735


13.
Nabholtz
JM

Buzdar
A

Pollak
M

Harwin
W

Burton
G

Mangalik
A

Steinberg
M

Webster
A

Euler
M


Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group (2000)
J Clin Oncol
2000
18
3758
3767

11078488


14.
Bonneterre
J

Thürlimann
B

Robertson
JF

Krzakowski
M

Mauriac
L

Koralewski
P

Vergote
I

Webster
A

Steinberg
M

Euler
M


Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study
J Clin Oncol
2000
18
3748
3757

11078487


15.
Paridaens
R

Dirix
L

Lohrisch
C

Beex
L

Nooij
M

Cameron
D

Biganzoli
L

Cufer
T

Duchateau
L

Hamilton
A

Lobelle
JP

Piccart
M


Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer
Ann Oncol
2003
14
1391
1398
10.1093/annonc/mdg362

12954578


16.
Ellis
MJ

Coop
A

Singh
B

Tao
Y

Llombart-Cussac
A

Janicke
F

Mauriac
L

Quebe-Fehling
E

Chaudri-Ross
HA

Evans
DB

Miller
WR


Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status
Cancer Res
2003
63
6523
6531

14559846


17.
Long
BJ

Jelovac
D

Handratta
V

Thiantanawat
A

MacPherson
N

Ragaz
J

Goloubeva
OG

Brodie
AM


Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model
J Natl Cancer Inst
2004
96
456
465

15026471


18.
Breast International Group (BIG) 1-98 Collaborative Group (2005) A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353:2747–2757. Erratum in: N Engl J Med 2006;354:2200

19.
Dowsett
M

Cuzick
J

Wale
C

Howell
T

Houghton
J

Baum
M


Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study
J Clin Oncol
2005
23
7512
7517
10.1200/JCO.2005.01.4829

16234518


20.
Rhodes
A

Jasani
B

Balaton
AJ

Barnes
DM

Anderson
E

Bobrow
LG

Miller
KD


Study of interlaboratory reliability and reproducibility of estrogen and progesterone receptor assays in Europe: documentation of poor reliability and identification of insufficient microwave antigen retrieval time as a major contributory element of unreliable assays
Am J Clin Pathol
2001
115
44
58
10.1309/H905-HYC1-6UQQ-981P

11190807


21.
Rasmussen BB, Regan MM, Lykkesfeldt AE, Dell’Orto P, Del Curto B, Henriksen KL, Mastropasqua MG, Thürlimann B, Viale G for the BIG 1-98 Collaborative Group, the IBCSG (2007) Central assessment of ER, PgR and HER2 in BIG 1-98 evaluating letrozole (L) vs. tamoxifen (T) as initial adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive breast cancer. J Clin Oncol 25(18S):12S. Abstract 538

22.
Mauriac
L

Keshaviah
A

Debled
M

Mouridsen
H

Forbes
J

Thuerlimann
B

Paridaens
R

Gelber
R

Castiglione-Gertsch
M

Goldhirsch
A


Predictors of early recurrence in postmenopausal women with hormone receptor positive breast cancer in the BIG 1-98 trial
Ann Oncol
2007
18
859
867
10.1093/annonc/mdm001

17301074


23.
Coates
AS

Keshaviah
A

Thürlimann
B

Mouridsen
H

Mauriac
L

Forbes
JF

Paridaens
R

Castiglione-Gertsch
M

Gelber
RD

Colleoni
M

Láng
I

Mastro
L

Smith
I

Chirgwin
J

Nogaret
JM

Pienkowski
T

Wardley
A

Jakobsen
EH

Price
KN

Goldhirsch
A


Five years of letrozole versus tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: further analyses and update of study BIG 1-98
J Clin Oncol
2007
25
486
492
10.1200/JCO.2006.08.8617

17200148


24.
Coates
AS

Mourisdsen
H

Sun
Z

Rabaglio
M

Castiglione-Gertsch
M

Thürlimann
B

Mauriac
L

Price
KN

Colleoni
M

Smith
I


Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: updated safety analysis of trial BIG 1-98
J Clin Oncol
2007
25
18S
8S

Coates AS, Mourisdsen H, Sun Z, Rabaglio M, Castiglione-Gertsch M, Thürlimann B, Mauriac L, Price KN, Colleoni M, Smith I (2007) Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: updated safety analysis of trial BIG 1-98. J Clin Oncol 25(18S):8S. Abstract 521 

25.
Chang
J

Powles
TJ

Ashley
SE

Gregory
RK

Tidy
VA

Treleaven
JG

Singh
R


The effect of tamoxifen and hormone replacement therapy on serum cholesterol, bone mineral density and coagulation factors in healthy postmenopausal women participating in a randomised, controlled tamoxifen prevention study
Ann Oncol
1996
7
671
675

8905024


26.
Goldhirsch A, Wood W, Gelber R, Coates A, Thürlimann B, Senn HJ, and Panel members (2007) Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 18:1133–1144

27.
http://www.nccn.org/


28.
Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG, Sahmoud T; ATAC Trialists’ Group (2002) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359:2131–2139. Erratum in: Lancet 2002;360:1520

29.
Baum M, Buzdar A, Cuzick J, Forbes J, Houghton J, Howell A, Sahmoud T; The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists’ Group (2003) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 98:1802–1810

30.
De Boer R, Burris H, Monnier A, Mouridsen H, O’Shaughnessy J, McIntyre K, Pritchard K, Smith I, Yardley D, on behalf of the H2H trial steering committee (2006) The Head to Head trial: letrozole vs anastrozole as adjuvant treatment of postmenopausal patients with node positive breast cancer. J Clin Oncol 24(18S):582s. Abstract 10672

31.
http://www.ibcsg.org/index.shtm


32.
Geisler
J

Lønning
PE


Aromatase inhibitors as adjuvant treatment of breast cancer
Crit Rev Oncol Hematol
2006
57
53
61
10.1016/j.critrevonc.2005.05.005

16337805


33.
Goss
PE

Ingle
JN

Martino
S

Robert
NJ

Muss
HB

Piccart
MJ

Castiglione
M

Tu
D

Shepherd
LE

Pritchard
KI

Livingston
RB

Davidson
NE

Norton
L

Perez
EA

Abrams
JS

Cameron
DA

Palmer
MJ

Pater
JL


Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17
J Natl Cancer Inst
2005
97
1262
1271

16145047


34.
Geisler
J

Haynes
B

Anker
G

Dowsett
M

Lonning
PE


Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study
J Clin Oncol
2002
20
751
757
10.1200/JCO.20.3.751

11821457


35.
Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, Jones SE, Alvarez I, Bertelli G, Ortmann O, Coates AS, Bajetta E, Dodwell D, Coleman RE, Fallowfield LJ, Mickiewicz E, Andersen J, Lonning PE, Cocconi G, Stewart A, Stuart N, Snowdon CF, Carpentieri M, Massimini G, Bliss JM, van de Velde C; Intergroup Exemestane Study (2004) A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350:1081–1092. Erratum in: N Engl J Med 2004;351:2461

36.
Coombes RC, Kilburn LS, Snowdon CF, Paridaens R, Coleman RE, Jones SE, Jassem J, Van de Velde CJ, Delozier T, Alvarez I, Del Mastro L, Ortmann O, Diedrich K, Coates AS, Bajetta E, Holmberg SB, Dodwell D, Mickiewicz E, Andersen J, Lønning PE, Cocconi G, Forbes J, Castiglione M, Stuart N, Stewart A, Fallowfield LJ, Bertelli G, Hall E, Bogle RG, Carpentieri M, Colajori E, Subar M, Ireland E, Bliss JM; Intergroup Exemestane Study (2007) Survival and safety of exemestane versus tamoxifen after 2–3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 369:559–570. Erratum in: Lancet 2007;369:906

37.
Goss
PE

Ingle
JN

Martino
S

Robert
NJ

Muss
HB

Piccart
MJ

Castiglione
M

Tu
D

Shepherd
LE

Pritchard
KI

Livingston
RB

Davidson
NE

Norton
L

Perez
EA

Abrams
JS

Therasse
P

Palmer
MJ

Pater
JL


A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer
N Engl J Med
2003
349
1793
1802
10.1056/NEJMoa032312

14551341


38.
Jakesz
R

Gnant
M

Greil
R

Tausch
C

Samonigg
H

Kwasny
W

Kubista
E

Stierer
M

Luschin
G

Mittlboeck
M


The benefits of sequencing adjuvant tamoxifen and anastrozole in postmenopausal women with hormone-responsive early breast cancer: 5 year-analysis of ABCSG Trial 8
Breast Cancer Res Treat
2005
94
suppl 1
S10

Jakesz R, Gnant M, Greil R, Tausch C, Samonigg H, Kwasny W, Kubista E, Stierer M, Luschin G, Mittlboeck M (2005) The benefits of sequencing adjuvant tamoxifen and anastrozole in postmenopausal women with hormone-responsive early breast cancer: 5 year-analysis of ABCSG Trial 8. Breast Cancer Res Treat 94(suppl 1):S10. Abstract 13 

39.
http://clinicaltrials.gov/ct/show/NCT00032136
. Accessed May 29, 2007


http://dx.doi.org/10.1007/s10549-007-9858-3





